Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers

被引:2
|
作者
Vu, Trung [1 ]
Fowler, Annaliese [2 ]
McCarty, Nami [2 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis IMM, Ctr Stem Cell & Regenerat Dis, Houston, TX 77030 USA
[2] Texas A&M Univ, Dept Biomed Engn, Houston, TX 77030 USA
关键词
TP53; liver cancer; TRIM family; cell cycle; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; GENE-EXPRESSION; P53; MICRORNAS; SURVIVAL; PROMOTES; MIR-34A;
D O I
10.3390/cancers15153792
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The p53 protein is an important tumor suppressor, and TP53 mutations are frequently low survival rates of cancer patients. Mutations in TP53 lead in loss of tumor suppressing functions which result in the development of tumors. Meanwhile, several tripartite motif (TRIM) proteins are known to regulate cell growth and cell cycle transition. However, the relationship between TRIM family genes and TP53 mutations in cancer remains unknown. In this study, we analyzed the links between TP53 mutations and TRIM family proteins and evaluated the role of TRIM family proteins in cancer patients with TP53 mutation. Our findings identified the TRIM family members that are highly expressed in TP53 mutant tumors and important for the cell growth in the context of TP53 mutations. The p53 protein is an important tumor suppressor, and TP53 mutations are frequently associated with poor prognosis in various cancers. Mutations in TP53 result in a loss of p53 function and enhanced expression of cell cycle genes, contributing to the development and progression of cancer. Meanwhile, several tripartite motif (TRIM) proteins are known to regulate cell growth and cell cycle transition. However, the prognostic values between TP53 and TRIM family genes in cancer are unknown. In this study, we analyzed the relationship between the TP53 mutations and TRIM family proteins and evaluated the prognostic significance of TRIM family proteins in cancer patients with P53 mutations. Our findings identified specific TRIM family members that are upregulated in TP53 mutant tumors and are associated with the activation of genes related to a cell-cycle progression in the context of TP53 mutations.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: Identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection
    Long, Jiang
    Wang, Yan
    Li, Man
    Tong, Wei-Min
    Jia, Ji-Dong
    Huang, Jian
    ONCOLOGY REPORTS, 2013, 30 (01) : 119 - 124
  • [22] Coordination of TP53 Abnormalities in Breast Cancer: Data from Analysis of TP53 Polymorphisms, Loss of Heterozygosity, Methylation, and Mutations
    Denisov, Evgeny V.
    Sukhanovskaya, Tatiana V.
    Dultseva, Tatiana S.
    Malinovskaya, Elena A.
    Litviakov, Nicolay V.
    Slonimskaya, Elena M.
    Choinzonov, Evgeny L.
    Cherdyntseva, Nadezhda V.
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (12) : 901 - 907
  • [23] Prognostic Significance of TP53 Mutations and Single Nucleotide Polymorphisms in Acute Myeloid Leukemia: A case Series and Literature Review
    Zeichner, Simon Blechman
    Alghamdi, Sarah
    Elhammady, Gina
    Poppiti, Robert John
    Castellano-Sanchez, Amilcar
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (04) : 1603 - 1609
  • [24] TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)
    Huszno, Joanna
    Grzybowska, Ewa
    ONCOLOGY LETTERS, 2018, 16 (01) : 34 - 40
  • [25] TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
    Poulain, Stephanie
    Roumier, Christophe
    Bertrand, Elisabeth
    Renneville, Aline
    Caillault-Venet, Aurelie
    Doye, Emmanuelle
    Geffroy, Sandrine
    Sebda, Sheherazade
    Nibourel, Olivier
    Nudel, Morgane
    Herbaux, Charles
    Renaud, Loic
    Tomowiak, Cecile
    Guidez, Stephanie
    Tricot, Sabine
    Roche-Lestienne, Catherine
    Quesnel, Bruno
    Preudhomme, Claude
    Leleu, Xavier
    CLINICAL CANCER RESEARCH, 2017, 23 (20) : 6325 - 6335
  • [26] Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms' tumor
    He, Changjing
    Qin, Huatao
    Tang, Haizhou
    Yang, Di
    Li, Yufeng
    Huang, Zhenwen
    Zhang, Donghu
    Lv, Changheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (19)
  • [27] TP53 Status and Response to Treatment in Breast Cancers
    Varna, Mariana
    Bousquet, Guilhem
    Plassa, Louis-Francois
    Bertheau, Philippe
    Janin, Anne
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011, : 1 - 9
  • [28] The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)
    Dong, Hua-Jie
    Zhou, Li-Tao
    Zhu, Dan-Xia
    Wang, Dong-Mei
    Fang, Cheng
    Zhu, Hua-Yuan
    Zhuang, Yun
    Miao, Kou-Rong
    Xu, Wei
    Li, Jian-Yong
    ANNALS OF HEMATOLOGY, 2011, 90 (06) : 709 - 717
  • [29] Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
    Tuna, Musaffe
    Ju, Zhenlin
    Yoshihara, Kosuke
    Amos, Christopher I.
    Tanyi, Janos L.
    Mills, Gordon B.
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 405 - 412
  • [30] Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers
    Malhotra, Lakshay
    Singh, Alankrita
    Kaur, Punit
    Ethayathulla, Abdul S.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024,